{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:56:35Z","timestamp":1776135395227,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NWO","award":["NWA 1389.20.157"],"award-info":[{"award-number":["NWA 1389.20.157"]}]},{"name":"Netherlands Heart Foundation","award":["CVON RECONNEXT"],"award-info":[{"award-number":["CVON RECONNEXT"]}]},{"name":"Netherlands Heart Foundation","award":["2020B008"],"award-info":[{"award-number":["2020B008"]}]},{"name":"Innovation Exchange Amsterdam"},{"name":"Atrial-Fibrillation-Innovation-Platform"},{"name":"StopAfib.org"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Interestingly, 30\u201350% of patients undergoing elective cardiothoracic surgery develop postoperative AF (PoAF). Unfortunately, preventive PoAF therapy is still suboptimal. In our previous studies, we showed that oral Geranylgeranylacetone (GGA) administration increased cardioprotective heat shock protein (HSP) protecting against AF onset and progression in clinically relevant animal model studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The GENIALITY study is a phase II single-center, double-blind, placebo-controlled randomized trial comparing the efficacy of GGA in preventing PoAF. Participants (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009146) are adult patients, without any registered history of AF, undergoing elective open-heart surgery for valvular disease, coronary artery bypass grafting, or concomitant, and are allocated with ratio 1:1 in treatment or placebo groups. Daily administration of 300 mg of GGA or placebo starts 5 days before until 3 days after surgery. Cardiac rhythm will be monitored using a Holter monitoring post-surgery until hospital discharge. Additionally, blood samples, right atrial appendage tissue, and epicardial adipose tissue will be collected to assess proteostasis levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The primary endpoint is the assessment of PoAF incidence in the GGA group compared to the placebo group. Secondary endpoints include the evaluation of HSP levels through biochemical analysis in both blood and atrial tissue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The GENIALITY study aims to reduce PoAF incidence in the GGA group compared to the placebo group. Herewith, we expect to obtain proof of concept for a beneficial effect of GGA in preventing PoAF in patients undergoing cardiothoracic surgery.\u00a0<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Clinical Trial Information System (CTIS) registry: 2024\u2013514743-28\u201300. Authorized on September 30th 2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10557-025-07693-2","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T06:44:51Z","timestamp":1744613091000},"page":"1589-1595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Geranylgeranylacetone as Prevention for Postoperative Atrial Fibrillation (GENIALITY)"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0283-3765","authenticated-orcid":false,"given":"Kennedy","family":"S. Ramos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soufiane","family":"Nassiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonoor F. J.","family":"Wijdeveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinier L.","family":"van der Palen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myrthe F.","family":"Kuipers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mellanie True","family":"Hills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Slijkerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel H.","family":"van Raalte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Louis","family":"Handoko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasja M. S.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimrat","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J. M.","family":"Klautz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etto C.","family":"Eringa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca J. J. M.","family":"Brundel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"issue":"5","key":"7693_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","journal-title":"Eur Heart J"},{"issue":"35","key":"7693_CR2","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","volume":"34","author":"BP Krijthe","year":"2013","unstructured":"Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746\u201351. https:\/\/doi.org\/10.1093\/eurheartj\/eht280.","journal-title":"Eur Heart J"},{"issue":"1","key":"7693_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41572-022-00347-9","volume":"8","author":"B Brundel","year":"2022","unstructured":"Brundel B, Ai X, Hills MT, et al. Atrial fibrillation Nat Rev Dis Primers. 2022;8(1):21. https:\/\/doi.org\/10.1038\/s41572-022-00347-9.","journal-title":"Atrial fibrillation Nat Rev Dis Primers"},{"issue":"7","key":"7693_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41569-019-0166-5","volume":"16","author":"D Dobrev","year":"2019","unstructured":"Dobrev D, Aguilar M, Heijman J, Guichard JB, Nattel S. Postoperative atrial fibrillation: mechanisms, manifestations and management. Nat Rev Cardiol. 2019;16(7):417\u201336. https:\/\/doi.org\/10.1038\/s41569-019-0166-5.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"7693_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/ejcts\/ezx039","volume":"52","author":"JW Greenberg","year":"2017","unstructured":"Greenberg JW, Lancaster TS, Schuessler RB, Melby SJ. Postoperative atrial fibrillation following cardiac surgery: a persistent complication. Eur J Cardiothorac Surg. 2017;52(4):665\u201372. https:\/\/doi.org\/10.1093\/ejcts\/ezx039.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"36","key":"7693_CR6","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314\u2013414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176.","journal-title":"Eur Heart J"},{"key":"7693_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.xjon.2021.01.014","volume":"6","author":"RK Kharbanda","year":"2021","unstructured":"Kharbanda RK, van Schie MS, Taverne Y, de Groot NMS, Bogers A. Novel insights in pathophysiology of postoperative atrial fibrillation. JTCVS Open. 2021;6:120\u20139. https:\/\/doi.org\/10.1016\/j.xjon.2021.01.014.","journal-title":"JTCVS Open"},{"issue":"11","key":"7693_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrcardio.2017.89","volume":"14","author":"RH Henning","year":"2017","unstructured":"Henning RH, Brundel B. Proteostasis in cardiac health and disease. Nat Rev Cardiol. 2017;14(11):637\u201353. https:\/\/doi.org\/10.1038\/nrcardio.2017.89.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"7693_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.yjmcc.2006.06.068","volume":"41","author":"BJ Brundel","year":"2006","unstructured":"Brundel BJ, Henning RH, Ke L, et al. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J Mol Cell Cardiol. 2006;41(3):555\u201362. https:\/\/doi.org\/10.1016\/j.yjmcc.2006.06.068.","journal-title":"J Mol Cell Cardiol"},{"issue":"12","key":"7693_CR10","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1161\/01.RES.0000252323.83137.fe","volume":"99","author":"BJ Brundel","year":"2006","unstructured":"Brundel BJ, Shiroshita-Takeshita A, Qi X, et al. Induction of heat shock response protects the heart against atrial fibrillation. Circ Res. 2006;99(12):1394\u2013402. https:\/\/doi.org\/10.1161\/01.RES.0000252323.83137.fe.","journal-title":"Circ Res"},{"key":"7693_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.yjmcc.2019.07.006","volume":"134","author":"X Hu","year":"2019","unstructured":"Hu X, Li J, van Marion DMS, Zhang D, Brundel B. Heat shock protein inducer GGA*-59 reverses contractile and structural remodeling via restoration of the microtubule network in experimental atrial fibrillation. J Mol Cell Cardiol. 2019;134:86\u201397. https:\/\/doi.org\/10.1016\/j.yjmcc.2019.07.006.","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"7693_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s12192-017-0799-4","volume":"22","author":"X Hu","year":"2017","unstructured":"Hu X, Van Marion DMS, Wiersma M, Zhang D, Brundel B. The protective role of small heat shock proteins in cardiac diseases: key role in atrial fibrillation. Cell Stress Chaperones. 2017;22(4):665\u201374. https:\/\/doi.org\/10.1007\/s12192-017-0799-4.","journal-title":"Cell Stress Chaperones"},{"key":"7693_CR13","doi-asserted-by":"publisher","unstructured":"van Wijk SW, Ramos KS, Brundel B. Cardioprotective role of heat shock proteins in atrial fibrillation: from mechanism of action to therapeutic and diagnostic target. Int J Mol Sci. 2021;22(1). https:\/\/doi.org\/10.3390\/ijms22010442.","DOI":"10.3390\/ijms22010442"},{"issue":"1","key":"7693_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.hrthm.2019.07.010","volume":"17","author":"DMS van Marion","year":"2020","unstructured":"van Marion DMS, Dorsch L, Hoogstra-Berends F, et al. Oral geranylgeranylacetone treatment increases heat shock protein expression in human atrial tissue. Heart Rhythm. 2020;17(1):115\u201322. https:\/\/doi.org\/10.1016\/j.hrthm.2019.07.010.","journal-title":"Heart Rhythm"},{"key":"7693_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2147\/DDDT.S176924","volume":"13","author":"DM van Marion","year":"2019","unstructured":"van Marion DM, Hu X, Zhang D, et al. Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation. Drug Des Devel Ther. 2019;13:345\u201364. https:\/\/doi.org\/10.2147\/DDDT.S176924.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"7693_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1161\/CIRCEP.111.965996","volume":"5","author":"YF Hu","year":"2012","unstructured":"Hu YF, Yeh HI, Tsao HM, et al. Electrophysiological correlation and prognostic impact of heat shock protein 27 in atrial fibrillation. Circ Arrhythm Electrophysiol. 2012;5(2):334\u201340. https:\/\/doi.org\/10.1161\/CIRCEP.111.965996.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"7","key":"7693_CR17","doi-asserted-by":"publisher","first-page":"e0133553","DOI":"10.1371\/journal.pone.0133553","volume":"10","author":"RA Meijering","year":"2015","unstructured":"Meijering RA, Wiersma M, van Marion DM, et al. RhoA activation sensitizes cells to proteotoxic stimuli by abrogating the HSF1-dependent heat shock response. PLoS ONE. 2015;10(7): e0133553. https:\/\/doi.org\/10.1371\/journal.pone.0133553.","journal-title":"PLoS ONE"},{"issue":"1","key":"7693_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/cvr\/cvn019","volume":"78","author":"M Sakabe","year":"2008","unstructured":"Sakabe M, Shiroshita-Takeshita A, Maguy A, et al. Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia. Cardiovasc Res. 2008;78(1):63\u201370. https:\/\/doi.org\/10.1093\/cvr\/cvn019.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"7693_CR19","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1016\/j.ijcard.2013.06.072","volume":"168","author":"SL Chang","year":"2013","unstructured":"Chang SL, Chen YC, Hsu CP, et al. Heat shock protein inducer modifies arrhythmogenic substrate and inhibits atrial fibrillation in the failing heart. Int J Cardiol. 2013;168(4):4019\u201326. https:\/\/doi.org\/10.1016\/j.ijcard.2013.06.072.","journal-title":"Int J Cardiol"},{"issue":"4","key":"7693_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000110654","volume":"75","author":"C Sakamoto","year":"2007","unstructured":"Sakamoto C, Ogoshi K, Saigenji K, et al. Comparison of the effectiveness of geranylgeranylacetone with cimetidine in gastritis patients with dyspeptic symptoms and gastric lesions: a randomized, double-blind trial in Japan. Digestion. 2007;75(4):215\u201324. https:\/\/doi.org\/10.1159\/000110654.","journal-title":"Digestion"},{"issue":"4","key":"7693_CR21","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000236032","volume":"80","author":"Y Niwa","year":"2009","unstructured":"Niwa Y, Nakamura M, Miyahara R, et al. Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects: a prospective randomized placebo-controlled double-blind cross-over study. Digestion. 2009;80(4):260\u20136. https:\/\/doi.org\/10.1159\/000236032.","journal-title":"Digestion"},{"issue":"4","key":"7693_CR22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3233\/JAD-190305","volume":"71","author":"S Yokoyama","year":"2019","unstructured":"Yokoyama S, Yoshinaga T, Matsuzaki J, Suzuki H. A randomized, double-blind, placebo-controlled study to evaluate the efficacy of teprenone in patients with Alzheimer\u2019s disease. J Alzheimers Dis. 2019;71(4):1187\u201399. https:\/\/doi.org\/10.3233\/JAD-190305.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"7693_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.121.056109","volume":"145","author":"M Aguilar","year":"2022","unstructured":"Aguilar M, Macle L, Deyell MW, et al. Influence of monitoring strategy on assessment of ablation success and postablation atrial fibrillation burden assessment: implications for practice and clinical trial design. Circulation. 2022;145(1):21\u201330. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056109.","journal-title":"Circulation"},{"key":"7693_CR24","doi-asserted-by":"publisher","unstructured":"Tzeis S, Gerstenfeld EP, Kalman J et al. 2024 European Heart Rhythm Association\/Heart Rhythm Society\/Asia Pacific Heart Rhythm Society\/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2024;26(4). https:\/\/doi.org\/10.1093\/europace\/euae043.","DOI":"10.1093\/europace\/euae043"},{"issue":"4","key":"7693_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ahj.2015.06.015","volume":"170","author":"RM Melduni","year":"2015","unstructured":"Melduni RM, Schaff HV, Bailey KR, et al. Implications of new-onset atrial fibrillation after cardiac surgery on long-term prognosis: a community-based study. Am Heart J. 2015;170(4):659\u201368. https:\/\/doi.org\/10.1016\/j.ahj.2015.06.015.","journal-title":"Am Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07693-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07693-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07693-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:00:41Z","timestamp":1766127641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07693-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7693"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07693-2","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"22 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is carried out in adherence to the Declaration of Helsinki and is approved by the local medical ethical committee of the Amsterdam University Medical Centra with the number MEC 2024.1014, recorded in the Clinical Trial Information System (CTIS) registry with the trial number 2024\u2013514743-28\u201300.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent for participation before study entry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Authors B.J.J.M.B, M.F.K, and N.M.S.d.G are founders of Atrial-Fibrillation-Innovation-Platform (AFIPonline.org), and author M.T.H. is the founder of StopAfib.org, both non-profit organizations. All other authors declare no competing interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}